Andrea Sotak is a life sciences strategic advisor, investor and corporate development leader, with a 20+ year track record of evaluating the commercial potential of pharmaceuticals across a range of therapeutic areas, modalities, and stages of clinical development. She currently serves as Head of Strategy & SVP Corporate Development at Weatherden, a UK-based firm that advises and supports companies by reducing strategic, technical and execution risk in drug development. Working with seed to mid-size biotech companies, VCs, and investors, she advises on matters ranging from corporate strategy to due diligence for acquisitions and partnerships. Andrea is also responsible for building and scaling Weatherden’s presence in North America.

From 2003 to 2019, Andrea served in various roles at DRI Capital, ultimately serving as President and Chief Investment Officer. Building the firm’s capabilities, Andrea led the Investment team, established and oversaw the Investor Relations and Operations functions, and co-led all fundraising and financial activities, tripling the size of the organization and increasing assets under management from $125M to over $2B.

Andrea earned an MBA from Queen’s University and a Bachelor of Science in Biochemistry from the University of Waterloo.